These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 8092125)

  • 1. Results of secondary prophylaxis in children with severe hemophilia.
    Manco-Johnson MJ; Nuss R; Geraghty S; Funk S; Kilcoyne R
    Am J Hematol; 1994 Oct; 47(2):113-7. PubMed ID: 8092125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
    Manco-Johnson MJ; Abshire TC; Shapiro AD; Riske B; Hacker MR; Kilcoyne R; Ingram JD; Manco-Johnson ML; Funk S; Jacobson L; Valentino LA; Hoots WK; Buchanan GR; DiMichele D; Recht M; Brown D; Leissinger C; Bleak S; Cohen A; Mathew P; Matsunaga A; Medeiros D; Nugent D; Thomas GA; Thompson AA; McRedmond K; Soucie JM; Austin H; Evatt BL
    N Engl J Med; 2007 Aug; 357(6):535-44. PubMed ID: 17687129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention of joint damage in hemophilic children with early prophylaxis].
    Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B
    Orthopade; 1999 Apr; 28(4):341-6. PubMed ID: 10335528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP.
    Berntorp E
    Baillieres Clin Haematol; 1996 Jun; 9(2):259-71. PubMed ID: 8800504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term low-dose secondary prophylaxis for severe and moderate hemophilia children with arthropathy in China: a single-center observation study].
    Wu RH; Wu XY; Zhang NN; Zhao L; Zhang JS; Zhen YZ; Peng Y
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):632-4. PubMed ID: 23906463
    [No Abstract]   [Full Text] [Related]  

  • 6. The use of continuous infusion of factor concentrates in the treatment of hemophilia.
    Bona RD; Weinstein RA; Weisman SJ; Bartolomeo A; Rickles FR
    Am J Hematol; 1989 Sep; 32(1):8-13. PubMed ID: 2502914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?
    Petrini P
    Haemophilia; 2001 Jan; 7(1):99-102. PubMed ID: 11136389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with prophylaxis in Sweden.
    Nilsson IM
    Semin Hematol; 1993 Jul; 30(3 Suppl 2):16-9. PubMed ID: 8367738
    [No Abstract]   [Full Text] [Related]  

  • 9. Update on treatment regimens: prophylaxis versus on-demand therapy.
    Manco-Johnson MJ
    Semin Hematol; 2003 Jul; 40(3 Suppl 3):3-9. PubMed ID: 14690062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orthopaedic evaluation in children with severe haemophilia A or B submitted to primary prophylaxis therapy in a coagulopathy treatment centre.
    De Podestá Haje D; Ono F; De Oliveira GB; Almeida J; De Paula JC; Batista Neto LV; Silva Barros SB
    Haemophilia; 2011 Mar; 17(2):228-32. PubMed ID: 21070500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis in haemophilic children.
    Liesner RJ
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S7-10. PubMed ID: 9351529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic factor replacement in hemophilia.
    Carcao MD; Aledort L
    Blood Rev; 2004 Jun; 18(2):101-13. PubMed ID: 15010149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylaxis for hemophilia: state of the art or state of confusion?
    Gruppo RA
    J Pediatr; 1998 Jun; 132(6):915-7. PubMed ID: 9627577
    [No Abstract]   [Full Text] [Related]  

  • 14. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
    Mahasandana C; Patharathienskul D; Suvatte V
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Articular and muscular hemorrhages in hemophilia A with anti-factor VIII antibodies. Treatment with selected batches of PPSB (factor IX concentrate)].
    Verroust F; Moussard C; Allain JP
    Presse Med; 1985 May; 14(19):1073-6. PubMed ID: 3158962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of prophyactic treatment on children with severe haemophilia.
    Liesner RJ; Khair K; Hann IM
    Br J Haematol; 1996 Mar; 92(4):973-8. PubMed ID: 8616096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
    Fischer K; Valentino L; Ljung R; Blanchette V
    Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The overall effectiveness of prophylaxis in severe haemophilia.
    Panicker J; Warrier I; Thomas R; Lusher JM
    Haemophilia; 2003 May; 9(3):272-8. PubMed ID: 12694517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When should prophylactic treatment in patients with haemophilia A and B start?--The German experience.
    Kreuz W; Escuriola-Ettingshausen C; Funk M; Schmidt H; Kornhuber B
    Haemophilia; 1998 Jul; 4(4):413-7. PubMed ID: 9873763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.